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Evaluation of Etest To Determine Tigecycline MICs
for Enterobacter Species
Tigecycline is often one of the few therapeutic options for
infections by multidrug-resistant Gram-negative bacteria.
Therefore, accurate MIC testing is critical. Since in many lab-
oratories tigecycline is not included in the routine panel of
antibiotics for susceptibility testing, tigecycline MICs are fre-
quently determined by Etest. However, previous studies have
shown that tigecycline MICs determined by Etest may be in-
fluenced by the brand of Mueller-Hinton (MH) agar, hypo-
thetically due to variations in the concentration of manganese
(2). Furthermore, for Acinetobacter species with MICs  2
mg/liter by Etest, the MIC was at least 2 doubling dilutions
lower by broth microdilution (BMD) (1). The aim of this study
was to evaluate the Etest as a method to determine tigecycline
MICs for Enterobacter species.
Tigecycline MICs were determined by BMD and Etest for
271 Enterobacter blood culture isolates (84% Enterobacter clo-
acae isolates and 16% Enterobacter aerogenes isolates) ob-
tained in 2006 and 2007 from 12 laboratories in the Nether-
lands. BMD was performed using Becton Dickinson (BD) MH
II medium for BMD (Merlin, Germany), according to Inter-
national Organization for Standardization (ISO) guideline
20776-1 (3) (the reference method of the Clinical and Labo-
ratory Standards Institute [CLSI]) and the European Commit-
tee on Antimicrobial Susceptibility Testing [EUCAST]). Etests
(bioMe´rieux, France) were performed on agar with the same
MH medium used in the BMD method and on Iso-Sensitest
agar (Oxoid, United Kingdom). In each experiment, Esche-
richia coli ATCC 25922 was used as a control strain. FDA and
EUCAST breakpoints were used (susceptible  2 mg/liter
and  1 mg/liter, respectively). The manganese concentrations
of the MH broth and both agars were determined using induc-
tion-coupled plasma atomic emission spectrometry (ICP-AES)
after the medium was dissolved with 65% nitric acid.
Compared to BMD, MICs determined by Etest were signifi-
cantly higher using either MH agar or Iso-Sensitest agar (Fig. 1
and Table 1). The correlation between the results of the BMD
and Etest on MH agar was high (Spearman’s nonparametric
correlation coefficient, 0.9; P  0.001), and the geometric mean
difference  standard deviation (SD) was 2.4  0.4 doubling
dilutions, pointing toward a systematic difference between the
methods. In 84% of the isolates, tigecycline MICs were 2 or more
doubling dilutions higher by Etest on MH agar compared to the
values found by BMD. The MICs determined by Etest on MH
agar were also significantly higher than by Etest on Iso-Sensitest
agar. No correlation between the manganese concentration in the
test medium and the tigecycline MIC was observed (Table 1).
The susceptibility rates were significantly higher by the BMD
method than by Etest (Table 1). When FDA breakpoints were
used, false nonsusceptibility was observed in 18% of the iso-
lates when performing Etest on MH agar. When EUCAST
breakpoints were used, 97% of isolates were susceptible by the
BMD method, whereas only 30% were susceptible by Etest on
MH agar, corresponding to false nonsusceptibility in 67% of
the isolates. No false-susceptible Etest results were observed
using either MH agar or Iso-Sensitest agar.
The MICs of the E. coli control strain were within the spec-
ified range (0.03 mg/liter to 0.25 mg/liter) for the three meth-
ods, although the MICs were 0.0325 mg/liter using BMD and
0.25 mg/liter using Etest on MH agar.
In conclusion, this study shows that tigecycline MICs for
Enterobacter species determined by Etest are significantly
higher than MICs determined by BMD. Differences in the
manganese concentration of the test media could not explainFIG. 1. Distribution of MICs of 271 Enterobacter isolates by BMD,Etest on BD Mueller-Hinton agar (MHA), and Etest on Iso-Sensitest
agar.
TABLE 1. Susceptibility results for 271 Enterobacter isolates using BMD, Etest on MHA (BD), and Etest on Iso-Sensitest agar
Method and medium
Manganese concn
in medium
(mg/kg)
MIC (mg/liter) Susceptibility rate (%)a:
50% 90% Geometricmean  SDb
EUCAST
(S  1)
FDA
(S  2)
BMD on BD MH broth 0.029c 0.25 1 0.42  0.41* 97** 100**
Etest
BD MH agar 0.043c 1.5 3 1.94  1.6* 30** 82**
Iso-Sensitest agar 0.48 0.5 1.5 0.88 1.2* 88** 94**
a Susceptibility rates found by using EUCAST and FDA susceptibility breakpoints (S), which were 1 and 2 mg/liter, respectively. , P  0.001 for comparisons
of susceptibility rates between each detection method using the Fisher exact test.
b , P  0.001 for comparisons of MICs between each detection method using a t test.
c The higher manganese concentration in the BD MH agar compared to BD MH broth could be explained by the manganese content of pure agar (0.002 mg/kg).
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the observed differences, and further research is required to
resolve this issue. We conclude that nonsusceptible tigecycline
Etest results should be confirmed using a BMD method. The
misclassification of isolates as tigecycline nonsusceptible may
deny patients an important antibiotic option.
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